Jesus Martinez, MD
Neurology · Memphis, TNNPI 1194916882
Payments from drug & device makers
Across 396 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$1K
- Novartis$904
- SK Life Science, Inc.$590
- Eisai Inc.$519
- AstraZeneca$504
- plus $4K from 32 others
What the payments were for
- Travel & lodging$97310%
- Food & beverage$8,60789%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 6 | $1,520 |
| AbbVie(2 entities) | 73 | $1,223 |
| Novartis | 49 | $904 |
| SK Life Science, Inc. | 27 | $590 |
| Eisai Inc. | 12 | $519 |
| AstraZeneca | 15 | $504 |
| Biogen | 18 | $411 |
| UCB, Inc. | 18 | $381 |
| Genentech USA, Inc. | 18 | $347 |
| Medtronic(2 entities) | 3 | $337 |
| Impel Pharmaceuticals Inc. | 16 | $277 |
| Neurocrine Biosciences, Inc. | 11 | $268 |
| Bristol Myers Squibb | 15 | $252 |
| Lilly USA, LLC | 12 | $201 |
| Argenx US, Inc. | 9 | $186 |
| Lundbeck LLC | 9 | $178 |
| Pfizer | 10 | $164 |
| EMD Serono, Inc. | 7 | $152 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $150 |
| Neurelis, Inc. | 8 | $145 |
| Amgen | 6 | $127 |
| Johnson & Johnson | 10 | $122 |
| Tanabe Pharma America, Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Amneal Pharmaceuticals LLC | 4 | $82 |
| GRT US Holding, Inc. | 5 | $81 |
| Acadia Pharmaceuticals Inc | 3 | $62 |
| GE HealthCare | 3 | $56 |
| C2n Diagnostics, LLC | 2 | $39 |
| Abbott | 2 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| CSL Behring | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,263
- Leqembi$362
- VNS - Sentiva$257
- ACTIVA PC$132
- Endurant$115
- SOLIRIS$108
How this compares
$9,643 in reported general payments places this provider in the 60th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 13 | $506,953 |
| Kesimpta PenOfatumumab | 26 | $195,928 |
| MayzentSiponimod | 12 | $133,821 |
| AustedoDeutetrabenazine | 13 | $107,911 |
| Dimethyl Fumarate | 27 | $102,146 |
| TysabriNatalizumab | 11 | $90,594 |
| UbrelvyUbrogepant | 72 | $79,926 |
| XcopriCenobamate | 30 | $62,550 |
| Aimovig AutoinjectorErenumab-Aooe | 61 | $44,959 |
| NamzaricMemantine Hcl/Donepezil Hcl | 41 | $44,258 |
| BotoxOnabotulinumtoxina | 26 | $37,966 |
| BanzelRufinamide | 12 | $37,404 |
| QuliptaAtogepant | 35 | $36,734 |
| AptiomEslicarbazepine Acetate | 14 | $34,382 |
| Emgality PenGalcanezumab-Gnlm | 47 | $30,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Namzaric, Botox, Qulipta | $1,223 | $198,884174 claims |
| NovartisMayzent | $904 | $133,82112 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $85 | $107,91113 claims |
| BiogenTysabri | $411 | $90,59411 claims |
| SK Life Science, Inc.Xcopri | $590 | $62,55030 claims |
| Eisai Inc.Banzel | $519 | $37,40412 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $18 | $34,38214 claims |
| UCB, Inc.Briviact | $381 | $28,59822 claims |
| PfizerNurtec Odt | $164 | $25,59214 claims |
| Neurelis, Inc.Valtoco | $145 | $9,44512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 361 neurology providers in Tennessee.
Other neurology in Memphis
- Lora McGillMemphis$7.5M
- Anthony NicholasMemphis$1.8M
- Mark LedouxMemphis$1.2M
- Tulio BertoriniMemphis$1M
- Lucas ElijovichMemphis$718K
- Rekha PillaiMemphis$355K
- Khalid AlsherbiniMemphis$249K
- Andrei AlexandrovMemphis$237K
- Ghaida ZaidMemphis$230K
- Nitin GoyalMemphis$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.